10 April 2018 - - Canada-based specialty pharmaceutical company Acerus Pharmaceuticals Corp. (TSX: ASP) has launched Urivarx in Canada less than 3 months after securing the exclusive Canadian rights to the product from San Diego, California-based non-prescription medicine and consumer care products company Innovus Pharmaceuticals, Inc. (OTCQB: INNV), the company said.
Acerus had previously planned for the Canadian launch of Urivarx in the second half of 2018, but the company has arranged for the product to be available in Canada via the Innovus supply chain.
This has helped Acerus, through its Innovus partner, to initiate direct to consumer campaigns and generate meaningful revenues in the first quarter.
The company intends to build on this solid start while its OTX platform and infrastructure are being implemented.
Acerus expects its multi-level commercial platform to be fully implemented in the coming months, which will also enable its expanded commercial team to proactively detail Urivarx to physicians.
Innovus Pharma is an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.
Acerus is focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience, with a primary focus in the field of men's and women's health.